Summary:
The purpose of this study is to investigate the effect of Lu AG06466 after multiple doses of 40 mg in patients with PTSD
Criteria:- The subject has a BMI of ≥18.5 and ≤32 kg/m2.
- The subject has PTSD, diagnosed according to Diagnostic and Statistical Manual Diploma in Social Medicine-5 (DSM-5), and confirmed by the Mini International Neuropsychiatric Interview (MINI).
- The subject has a Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total score ≥28 at screening and baseline.
- The subject has alterations in arousal and reactivity, confirmed on CAPS-5.
- The subject has ongoing sleep disturbances, confirmed on CAPS-5.
- The subject is willing to discontinue all prohibited medications during the study and to complete a washout of psychotropic medication during the washout period.
- The subject does not have any MRI contraindications.
Qualified Participants May Receive:
Monetary compensation for participating.